Omaveloxolone is a semi-synthetic triterpenoid compound that functions as an Nrf2 activator. It is approved as a pharmaceutical raw material for use in Friedreich's ataxia in adults and adolescents aged 16 years and older.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1474034-05-3
Pitavastatin calcium
pharmaceutical raw material
Bosentan
pharmaceutical raw material
Desethylchloroquine
pharmaceutical raw material
Calcipotriene hydrate
pharmaceutical raw material
N-[(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicen-4a-yl]-2,2-difluoropropanamide
RJCWBNBKOKFWNY-IDPLTSGASA-N
C[C@@]12CC[C@]3(CCC(C[C@H]3[C@H]1C(=O)C=C4[C@]2(CC[C@@H]5[C@@]4(C=C(C(=O)C5(C)C)C#N)C)C)(C)C)NC(=O)C(C)(F)F